Fernández DJ, Zapata BE, Santiesteban SX, Lescay BO, Rosell TL

Language: Spanish
References: 25
Page: 113-121
PDF size: 86.91 Kb.

ABSTRACT

In this work it is commented about the use and abuse of prostaglandins which form part of the so called autacoid agents or local hormones, as well as of their action mechanisms, biosynthesis, metabolism, pharmacological actions, clinical uses, administration schedules and adverse reactions. Likewise, it is stated that prostaglandins have very well-known effects on the smooth muscle and the platelets, and they act on other important systems, such as the digestive, reproductive and the nervous systems, and in the nervous autonomous posganglionar endings, the sensorial nerves endings, the endocrine organs and the fatty tissue.

REFERENCES

1. Funds Dissemination Committee. FDC Reports. The Pink Sheet. 1995; 57: 16.

2. Funds Dissemination Committee. FDC Reports. The Pink Sheet. 1995; 57: 8-9.

3. Frölich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenese isoenzymes. Trends Pharmacol Sci. 1997; 18(1): 30-4.

4. Goodman and Gilman's las bases farmacológicas de la terapéutica. 9 ed. México, D.F.: McGraw-Hill Interamericana; 1988. p. 601-6.

5. Gilman AG, Rall TW, Nies AS. Goodman and Gilman's las bases farmacológicas de la terapéutica. 9 ed. México, D.F.: McGraw-Hill Interamericana; 1988.

6. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International Union of Pharmacology classification of receptors for 5- hydroxytryptamine (Serotonin). Pharmacol Rev. 1994; 46(2):157-203.

7. Melmon KL, Morrelli H, Hoffman BB, Neirenberg D. Melmon and Morrelli's Clinical Pharmacology: Basic Principles of Therapeutics. 3 ed. New York: McGraw-Hill Professional; 1992.

8. Clark WG, Brater GD, Johnson AR. Goth. Farmacología Médica. Saint Louis: Mosby; 1993.

9. Smith CM, Reynard AM. Farmacología. Buenos Aires: Editora Médica Panamericana; 1993.

10. Rang HP, Dale MM. Farmacología. New York: Churchill Livingstone; 1992.

11. Velazco A, Lorenzo P, Serrano JS, Andrés Trelles F. Farmacología. 16 ed. México, D.F.: McGraw-Hill Interamericana; 1993.

12. Yaffe SF, Aranda, JV. Pediatric Pharmacology. Philadelphia: W.B. Saunders; 1992.

13. Dukes MN. Meyler's side effects of drugs. 12 ed. Ámsterdam: Elsevier Science; 1992.

14. Litter M. Farmacología experimental y clínica. Buenos Aires: El Ateneo; 1986.

15. Harrinson TR. Principios de medicina interna. 16 ed. México, D.F.: McGraw-Hill Interamericana; 2006.

16. Esplugues JV, Barrachina MD, Beltrán B, Calatayud S, Whittle BJR, Moncada S. Inhibition of gastric acid secretion by stress: a protective reflex mediated by cerebral nitric oxide. Proc Natl Acad Sci USA. 1996; 93: 14839-44.

17. Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol. 1995; 57: 683-706.

18. Giles H, Leff P. The biology and pharmacology of PGD2. Prostaglandins. 1988; 35(2): 277-300.

19. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta. 1996; 1299(1): 125-140.

20. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. Ann Intern Med. 1994; 120(3): 227-37.

21. Morrow JD, Robert LJ. The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol. 1996; 51(1): 1-9.

22. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol. 1992; 263(2): 181-191.

23. Wise H, Jones RL. Focus on prostacyclin and its novel mimetics. Trends Pharmacol Sci. 1996; 17(1): 17-21.

24. Volkow ND. Los medicamentos de prescripción: abuso y adicción [citado 3 Feb 2014].

25. Pérez Hernández BG. Reacciones adversas a los medicamentos y adicción a otras sustancias. En: Morón Rodríguez FG, Levy Rodríguez M. Farmacología General. La Habana: Editorial Ciencias Médicas; 2002. p. 70-89.